Fernández-Nogales, MartaHernández, FélixMiguez, AndrésAlberch i Vié, Jordi, 1959-Ginés Padrós, SilviaPérez Navarro, EstherLucas, José J.2022-03-282022-03-282015-09-010964-6906https://hdl.handle.net/2445/184430Huntington's disease (HD) is a hereditary neurodegenerative disorder characterized by brain atrophy particularly in striatum leading to personality changes, chorea and dementia. Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase in the crossroad of many signaling pathways that is highly pleiotropic as it phosphorylates more than hundred substrates including structural, metabolic, and signaling proteins. Increased GSK-3 activity is believed to contribute to the pathogenesis of neurodegenerative diseases like Alzheimer's disease and GSK-3 inhibitors have been postulated as therapeutic agents for neurodegeneration. Regarding HD, GSK-3 inhibitors have shown beneficial effects in cell and invertebrate animal models but no evident efficacy in mouse models. Intriguingly, those studies were performed without interrogating GSK-3 level and activity in HD brain. Here we aim to explore the level and also the enzymatic activity of GSK-3 in the striatum and other less affected brain regions of HD patients and of the R6/1 mouse model to then elucidate the possible contribution of its alteration to HD pathogenesis by genetic manipulation in mice. We report a dramatic decrease in GSK-3 levels and activity in striatum and cortex of HD patients with similar results in the mouse model. Correction of the GSK-3 deficit in HD mice, by combining with transgenic mice with conditional GSK-3 expression, resulted in amelioration of their brain atrophy and behavioral motor and learning deficits. Thus, our results demonstrate that decreased brain GSK-3 contributes to HD neurological phenotype and open new therapeutic opportunities based on increasing GSK-3 activity or attenuating the harmful consequences of its decrease.16 p.application/pdfeng(c) Fernández-Nogales, Marta et al., 2015Corea de HuntingtonProteïnes quinasesInhibidors enzimàticsMalalties neurodegenerativesCinètica enzimàticaHuntington's choreaProtein kinasesEnzyme inhibitorsNeurodegenerative DiseasesEnzyme kineticsinfo:eu-repo/semantics/article6546172022-03-28info:eu-repo/semantics/openAccess